Research programme: targeted platinum theranostics - Nemucore Medical Innovations

Drug Profile

Research programme: targeted platinum theranostics - Nemucore Medical Innovations

Alternative Names: NMI-350

Latest Information Update: 25 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nemucore Medical Innovations
  • Class Gadolinium-containing contrast agents; Platinum complexes; Radiopharmaceuticals; Sphingolipids
  • Mechanism of Action Diagnostic imaging enhancers; DNA cross linking agents; DNA synthesis inhibitors; Folate receptor 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ovarian cancer

Most Recent Events

  • 23 May 2016 Preclinical trials in Ovarian cancer (Diagnosis) in USA (Parenteral)
  • 23 May 2016 Preclinical trials in Ovarian cancer in USA (Parenteral)
  • 12 May 2016 Early research in Ovarian cancer (Diagnosis) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top